Lipid-enriched diet rescues lethality and slows down progression in a murine model of VCP-associated disease

Human Molecular Genetics

Volumn 23, Issue 5, 2014, Pages 1333-1344

  Llewellyn, Katrina J ^a   Nalbandian, Angèle ^a   Jung, Kwang Mook ^a   Nguyen, Christopher ^a   Avanesian, Agnesa ^a   Mozaffar, Tahseen ^b   Piomelli, Daniele ^a,c   Kimonis, Virginia E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASES; ANIMALS; AUTOPHAGY; CELL CYCLE PROTEINS; DIET; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ELECTROMYOGRAPHY; GENETIC ASSOCIATION STUDIES; HETEROZYGOTE; HOMOZYGOTE; KYPHOSIS; LIPID METABOLISM; MICE; MICE, KNOCKOUT; MITOCHONDRIA; MUSCLE, SKELETAL; OSTEITIS DEFORMANS;

EID: 84894049194     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddt523     Document Type: Article

References (57)

1. Kimonis, V.E., Kovach, M.J., Waggoner, B., Leal, S., Salam, A., Rimer, L., Davis, K., Khardori,R. and Gelber, D. (2000) Clinical and molecular studies in a unique family with autosomal dominant limb-girdle muscular dystrophy and Paget disease of bone. Genet. Med., 2, 232-241.
2. Kovach, M.J., Ruiz, J., Kimonis, K., Mueed, S., Sinha, S., Higgins, C., Elble, S., Elble, R. and Kimonis, V.E. (2001) Genetic heterogeneity in autosomal dominant essential tremor. Genet. Med., 3, 197-199.
3. Nalbandian, A., Donkervoort, S., Dec, E., Badadani, M., Katheria, V., Rana, P., Nguyen, C., Mukherjee, J., Caiozzo, V., Martin, B. et al. (2011) The multiple faces of valosin-containing protein-associated diseases: inclusion body myopathy with Paget's disease of bone, frontotemporal dementia, and amyotrophic lateral sclerosis. J. Mol. Neurosci., 45, 522-531.
4. Watts, G.D., Thorne, M., Kovach, M.J., Pestronk, A. and Kimonis, V.E. (2003) Clinical and genetic heterogeneity in chromosome 9p associated hereditary inclusion body myopathy: exclusion of GNE and three other candidate genes. Neuromuscul. Disord., 13, 559-567.
5. Kimonis, V.E., Mehta, S.G., Fulchiero, E.C., Thomasova, D., Pasquali, M., Boycott, K., Neilan, E.G., Kartashov, A., Forman, M.S., Tucker, S. et al. (2008) Clinical studies in familial VCP myopathy associated with Paget disease of bone and frontotemporal dementia. Am. J. Med. Genet., 146, 745-757.
6. Watts, G.D., Wymer, J., Kovach, M.J., Mehta, S.G., Mumm,S., Darvish, D., Pestronk, A., Whyte, M.P. and Kimonis, V.E. (2004) Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat. Genet., 36, 377-381.
7. Kimonis, V.E., Fulchiero, E., Vesa, J. and Watts, G. (2008) VCP disease associated with myopathy, paget disease of bone and frontotemporal dementia: Review of a unique disorder. Biochim. Biophys. Acta, 1782, 744-748.
8. Nalbandian, A., Ghimbovschi, S., Radom-Aizik, S., Dec, E., Vesa, J., Martin, B., Knoblach, S., Smith, C., Hoffman, E. and Kimonis, V.E. (2012) Global gene profiling of VCP-associated inclusion body myopathy. Clin. Transl. Sci., 5, 226-234.
9. Ju, J.S., Fuentealba, R.A., Miller, S.E., Jackson, E., Piwnica-Worms, D., Baloh, R.H. and Weihl, C.C. (2009) Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease. J. Cell Biol., 187, 875-888.
10. Vesa, J., Su, H., Watts, G.D., Krause, S., Walter, M.C., Martin, B., Smith, C., Wallace, D.C. and Kimonis, V.E. (2009) Valosin containing protein associated inclusion body myopathy: abnormal vacuolization, autophagy and cell fusion in myoblasts. Neuromuscul. Disord., 19, 766-772.
11. Lee, H.S., Daniels, B.H., Salas, E., Bollen, A.W., Debnath, J. and Margeta, M. (2012) Clinical utility of LC3 and p62 immunohistochemistry in diagnosis of drug-induced autophagic vacuolar myopathies: a case-control study. PLoS One, 7, e36221.
12. Malicdan, M.C. and Nishino, I. (2012) Autophagy in lysosomal myopathies. Brain Pathol., 22, 82-88.
13. Shea, L. and Raben, N. (2009) Autophagy in skeletal muscle: implications for Pompe disease. Int. J. Clin. Pharmacol. Ther., 47 (Suppl 1), S42-S47.
14. Lunemann, J.D., Schmidt, J., Dalakas, M.C. and Munz, C. (2007) Macroautophagy as a pathomechanism in sporadic inclusion body myositis. Autophagy, 3, 384-386.
15. Goode, A. and Layfield, R. (2010) Recent advances in understanding the molecular basis of Paget disease of bone. J. Clin. Pathol., 63, 199-203.
16. Hirano, M., Nakamura, Y., Saigoh, K., Sakamoto, H., Ueno, S., Isono, C., Miyamoto, K., Akamatsu, M., Mitsui, Y. and Kusunoki, S. (2013) Mutations in the gene encoding p62 in Japanese patients with amyotrophic lateral sclerosis. Neurology, 80, 458-463.
17. Hiruma, Y., Kurihara, N., Subler, M.A., Zhou, H., Boykin, C.S., Zhang, H., Ishizuka, S., Dempster, D.W., Roodman, G.D. and Windle, J.J. (2008) A SQSTM1/p62 mutation linked to Paget's disease increases the osteoclastogenic potential of the bone microenvironment.Hum.Mol. Genet., 17, 3708-3719.
18. Laurin, N., Brown, J.P., Morissette, J. and Raymond, V. (2002) Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am. J. Hum. Genet., 70, 1582-1588.
19. Rhodes, E.C., Johnson-Pais, T.L., Singer, F.R., Ankerst, D.P., Bruder, J.M., Wisdom, J., Hoon, D.S., Lin, E., Bone, H.G., Simcic, K.J. et al. (2008) Sequestosome 1 (SQSTM1) mutations in Paget's disease of bone from the United States. Calcif. Tissue Int., 82, 271-277.
20. Rubino, E., Rainero, I., Chio, A., Rogaeva, E., Galimberti, D., Fenoglio, P., Grinberg, Y., Isaia, G., Calvo, A., Gentile, S. et al. (2012) SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Neurology, 79, 1556-1562.
21. Teyssou, E., Takeda, T., Lebon, V., Boillee, S., Doukoure, B., Bataillon, G., Sazdovitch, V., Cazeneuve, C., Meininger, V., Leguern, E. et al. (2013) Mutations in SQSTM1 encoding p62 in amyotrophic lateral sclerosis: genetics and neuropathology. Acta Neuropathol., 125, 511-522.
22. Kim, N.C., Tresse, E., Kolaitis, R.M., Molliex, A., Thomas, R.E., Alami, N.H., Wang, B., Joshi, A., Smith, R.B., Ritson, G.P. et al. (2013) VCP is essential for mitochondrial quality control by PINK1/Parkin and this function is impaired by VCP mutations. Neuron., 78, 65-80.
23. Bartolome, F., Wu, H.C., Burchell, V.S., Preza, E., Wray, S., Mahoney, C.J., Fox, N.C., Calvo, A., Canosa, A., Moglia, C. et al. (2013) Pathogenic VCP mutations induce mitochondrial uncoupling and reduced ATP levels. Neuron, 78, 57-64.
24. Nalbandian, A., Llewellyn, K.J., Badadani, M., Yin, H.Z., Nguyen, C., Katheria, V., Watts, G., Mukherjee, J., Vesa, J., Caiozzo, V. et al. (2013) A progressive translational mouse model of human valosin-containing protein disease: the VCP(R155H/+) mouse. Muscle Nerve, 47, 260-270.
25. Yin, H.Z., Nalbandian, A., Hsu, C.I., Li, S., Llewellyn, K.J., Mozaffar, T., Kimonis, V.E. and Weiss, J.H. (2012) Slow development of ALS-like spinal cord pathology in mutant valosin-containing protein gene knock-in mice. Cell Death Dis., 3, e374.
26. Nalbandian, A., Llewellyn, K.J., Kitazawa, M., Yin, H.Z., Badadani, M., Khanlou, N., Edwards, R., Nguyen, C., Mukherjee, J., Mozaffar, T. et al. (2012) The homozygote VCPR155H/R155H mouse model exhibits accelerated human VCP-associated disease pathology. PLoS One, 7, e46308.
27. Baranano, K.W. and Hartman, A.L. (2008) The ketogenic diet: uses in epilepsy and other neurologic illnesses. Curr. Treat Options Neurol., 10, 410-419.
28. Evangeliou, A., Vlachonikolis, I., Mihailidou, H., Spilioti, M., Skarpalezou, A., Makaronas, N., Prokopiou, A., Christodoulou, P., Liapi-Adamidou, G., Helidonis, E. et al. (2003) Application of a ketogenic diet in children with autistic behavior: pilot study. J. Child Neurol., 18, 113-118.
29. Gasior, M., Rogawski, M.A. and Hartman, A.L. (2006) Neuroprotective and disease-modifying effects of the ketogenic diet. Behav. Pharmacol., 17, 431-439.
30. Jozwiak, S., Kossoff, E.H. and Kotulska-Jozwiak, K. (2011) Dietary treatment of epilepsy: rebirth of an ancient treatment. Neurol. Neurochir. Pol., 45, 370-378.
31. Siva, N. (2006) Can ketogenic diet slow progression of ALS? Lancet Neurol., 5, 476.
32. Stafstrom, C.E. and Rho, J.M. (2012) The ketogenic diet as a treatment paradigm for diverse neurological disorders. Front Pharmacol., 3, 59.
33. Camargo, N., Brouwers, J.F., Loos, M., Gutmann, D.H., Smit, A.B. and Verheijen, M.H. (2012) High-fat diet ameliorates neurological deficits caused by defective astrocyte lipid metabolism. FASEB J., 26, 4302-4315.
34. Moresi, V., Carrer, M., Grueter, C.E., Rifki, O.F., Shelton, J.M., Richardson, J.A., Bassel-Duby, R. and Olson, E.N. (2012) Histone deacetylases 1 and 2 regulate autophagy flux and skeletal muscle homeostasis in mice. Proc. Nat. Acad. Sci. USA, 109, 1649-1654.
35. Turner, N., Bruce, C.R., Beale, S.M., Hoehn, K.L., So, T., Rolph, M.S. and Cooney, G.J. (2007) Excess lipid availability increases mitochondrial fatty acid oxidative capacity in muscle: evidence against a role for reduced fatty acid oxidation in lipid-induced insulin resistance in rodents. Diabetes, 56, 2085-2092.
36. Li, B., Tong, L., Jia, G. and Sun, R. (2013) Effects of ketogenic diet on the clinical and electroencephalographic features of children with drug therapy-resistant epilepsy. Exp. Ther. Med., 5, 611-615.
37. Peuscher, R., Dijsselhof, M.E., Abeling, N.G., Van Rijn, M., Van Spronsen, F.J. and Bosch, A.M. (2012) The ketogenic diet is well tolerated and can be effective in patients with argininosuccinate lyase deficiency and refractory epilepsy. JIMD Reports, 5, 127-130.
38. Luan, G., Zhao, Y., Zhai, F., Chen, Y. and Li, T. (2012) Ketogenic diet reduces Smac/Diablo and cytochrome c release and attenuates neuronal death in a mouse model of limbic epilepsy. Brain Res. Bull., 89, 79-85.
39. Noh, H.S., Kim, Y.S. and Choi, W.S. (2008) Neuroprotective effects of the ketogenic diet. Epilepsia, 49 (Suppl 8), 120-123.
40. Koga, H., Kaushik, S. and Cuervo, A.M. (2010) Altered lipid content inhibits autophagic vesicular fusion. FASEB. J., 24, 3052-3065.
41. Mei, S., Ni, H.M., Manley, S., Bockus, A., Kassel, K.M., Luyendyk, J.P., Copple, B.L. and Ding, W.X. (2011) Differential roles of unsaturated and saturated fatty acids on autophagy and apoptosis in hepatocytes. J. Pharmacol. Exp. Ther., 339, 487-498.
42. Bruni, P. and Donati, C. (2008) Pleiotropic effects of sphingolipids in skeletal muscle. Cell Mol. Life Sci., 65, 3725-3736.
43. Buren, J., Lai, Y.C., Lundgren, M., Eriksson, J.W. and Jensen, J. (2008) Insulin action and signalling in fat and muscle from dexamethasone-treated rats. Arch. Biochem. Biophys., 474, 91-101.
44. Holland, W.L., Brozinick, J.T., Wang, L.P., Hawkins, E.D., Sargent, K.M., Liu, Y., Narra, K., Hoehn, K.L., Knotts, T.A., Siesky, A. et al. (2007) Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab., 5, 167-179.
45. Turpin, S.M., Lancaster, G.I., Darby, I., Febbraio, M.A. and Watt, M.J. (2006) Apoptosis in skeletal muscle myotubes is induced by ceramides and is positively related to insulin resistance. Am. J. Physiol. Endocrinol. Metab., 291, E1341-E1350.
46. Cutler, R.G., Pedersen, W.A., Camandola, S., Rothstein, J.D. and Mattson, M.P. (2002) Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann. Neurol., 52, 448-457.
47. Filippov, V., Song, M.A., Zhang, K., Vinters, H.V., Tung, S., Kirsch, W.M., Yang, J. and Duerksen-Hughes, P.J. (2012) Increased ceramide in brains with Alzheimer's and other neurodegenerative diseases. J. Alzheimers Dis., 29, 537-547.
48. Rabinowitz, J.D. and White, E. (2010) Autophagy and metabolism. Science, 330, 1344-1348.
49. Schiaffino, S., Mammucari, C. and Sandri, M. (2008) The role of autophagy in neonatal tissues: just a response to amino acid starvation? Autophagy, 4, 727-730.
50. Ralston, S.H. (2013) Clinical practice. Paget's disease of bone. N. Engl. J. Med., 368, 644-650.
51. Ralston, S.H. and Layfield, R. (2012) Pathogenesis of Paget disease of bone. Calcif. Tissue Int., 91, 97-113.
52. Daroszewska, A., van 't Hof, R.J., Rojas, J.A., Layfield, R., Landao-Basonga, E., Rose, L., Rose, K. and Ralston, S.H. (2011) A point mutation in the ubiquitin-associated domain of SQSMT1 is sufficient to cause a Paget's disease-like disorder in mice. Hum. Mol. Genet., 20, 2734-2744.
53. Chamoux, E., Couture, J., Bisson, M., Morissette, J., Brown, J.P. and Roux, S. (2009) The p62 P392L mutation linked to Paget's disease induces activation of human osteoclasts. Mol. Endocrinol., 23, 1668-1680.
54. Fecto, F., Yan, J., Vemula, S.P., Liu, E., Yang, Y., Chen, W., Zheng, J.G., Shi, Y., Siddique, N., Arrat, H. et al. (2011) SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch. Neurol., 68, 1440-1446.
55. Badadani, M., Nalbandian, A., Watts, G.D., Vesa, J., Kitazawa, M., Su, H., Tanaja, J., Dec, E., Wallace, D.C., Mukherjee, J. et al. (2010)VCPassociated inclusion body myopathy and Paget disease of bone knock-in mouse model exhibits tissue pathology typical of human disease. PLoS One, 5, e13183.
56. Ross, J.M. (2011) Visualization of mitochondrial respiratory function using cytochrome c oxidase/succinate dehydrogenase (COX/SDH) double-labeling histochemistry. J. Vis. Exp., 57, e3266.
57. Jung, K.M., Clapper, J.R., Fu, J., D'Agostino, G., Guijarro, A., Thongkham, D., Avanesian, A., Astarita, G., DiPatrizio, N.V., Frontini, A. et al. (2012) 2-arachidonoylglycerol signaling in forebrain regulates systemic energy metabolism. Cell Metab., 15, 299-310.